As Abbott Laboratories (ABT) Stock Price Declined, Old West Investment Management LLC Has Trimmed by $3.36 Million Its Stake

February 14, 2018 - By Ellis Scott

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.01, from 0.88 in 2017Q2. It dived, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Berkshire Asset Mngmt Ltd Liability Corporation Pa has 1.48% invested in Abbott Laboratories (NYSE:ABT). Private Wealth Advisors invested in 9,826 shares. Outfitter Advisors Limited reported 4,731 shares. Clean Yield Grp Inc has 11,845 shares for 0.26% of their portfolio. Pictet Asset Ltd reported 1.43M shares. Eubel Brady & Suttman Asset Management owns 8,917 shares or 0.15% of their US portfolio. Hightower Advisors Limited Liability Corporation holds 0.28% or 623,384 shares. Andra Ap invested in 0.36% or 284,500 shares. Tradition Ltd Liability Company has 1.81% invested in Abbott Laboratories (NYSE:ABT). Credit Agricole S A invested 0.14% of its portfolio in Abbott Laboratories (NYSE:ABT). Pension reported 1.36 million shares. Cim Lc invested 0.16% in Abbott Laboratories (NYSE:ABT). Connors Investor, a Pennsylvania-based fund reported 194,860 shares. 129,620 were reported by Cibc Markets Incorporated. Fmr Lc, a Massachusetts-based fund reported 12.36 million shares.

Since August 16, 2017, it had 0 insider purchases, and 7 insider sales for $31.71 million activity. Ford Robert B had sold 42,665 shares worth $2.69 million on Tuesday, January 30. Contreras Jaime sold $2.74M worth of Abbott Laboratories (NYSE:ABT) on Friday, September 22. Another trade for 196,550 shares valued at $9.73M was made by Fussell Stephen R on Wednesday, August 16. Blaser Brian J sold 27,733 shares worth $1.73M.

Old West Investment Management Llc decreased its stake in Abbott Laboratories (ABT) by 24.12% based on its latest 2017Q3 regulatory filing with the SEC. Old West Investment Management Llc sold 63,331 shares as the company’s stock declined 3.42% while stock markets rallied. The hedge fund held 199,223 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.63M, down from 262,554 at the end of the previous reported quarter. Old West Investment Management Llc who had been investing in Abbott Laboratories for a number of months, seems to be less bullish one the $100.33B market cap company. The stock increased 0.40% or $0.23 during the last trading session, reaching $57.64. About 5.82 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 14, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

More news for Abbott Laboratories (NYSE:ABT) were recently published by: Startribune.com, which released: “St. Jude Medical delivers sales growth for Abbott Labs” on January 25, 2018. Cnbc.com‘s article titled: “Abbott’s fourth-quarter results, 2018 profit forecast beat estimates” and published on January 24, 2018 is yet another important article.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. Wells Fargo maintained the shares of ABT in report on Thursday, August 27 with “Buy” rating. The stock has “Buy” rating by Jefferies on Thursday, August 4. The stock has “Buy” rating by Jefferies on Wednesday, January 24. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Wednesday, January 24 by Stifel Nicolaus. The rating was maintained by Stifel Nicolaus on Wednesday, April 19 with “Buy”. The stock of Abbott Laboratories (NYSE:ABT) has “Overweight” rating given on Thursday, September 28 by Barclays Capital. The firm has “Buy” rating given on Wednesday, June 21 by BTIG Research. The company was upgraded on Thursday, January 25 by William Blair. Jefferies reinitiated the stock with “Buy” rating in Thursday, June 29 report. Barclays Capital maintained the stock with “Overweight” rating in Thursday, October 19 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.